Getting personal with myelodysplastic syndromes: is now the right time?. Issue 4 (3rd April 2019)

• Record Type: Journal Article
• Authors: Chokr, Nora; Pine, Alexander B.; Bewersdorf, Jan Philipp; Shallis, Rory M.; Stahl, Maximilian; Zeidan, Amer M.
• Is Part Of: Expert review of hematology. Volume 12:Issue 4(2019)
• Page Start: 215
• Page End: 224
• Publication Date: 2019-04-03
• Subjects: Genetics -- myelodysplastic syndrome -- MDS -- mutations -- next generation sequencing -- NGS; Hematology -- Periodicals; 616.15005
• DOI: 10.1080/17474086.2019.1592673
• Languages: English
• ISSNs: 1747-4086

Abstract

ABSTRACT: Introduction : Commonly used scoring systems rely on blood counts, histological and cytological examination of bone marrow and peripheral blood as well as cytogenetic assessments to estimate prognosis of patients with myelodysplastic syndromes (MDS) and guide therapy decisions. Next-generation sequencing (NGS) has identified recurrent genetic abnormalities in up to 90% of patients with MDS and may provide important information regarding the pathogenesis of the disease, diagnostic and prognostic evaluation, and therapy selection. Areas covered : Herein, the authors review the role of NGS in diagnosis, treatment, and prognosis of MDS at various disease stages, and discuss advantages and caveats of incorporating molecular genetics in routine management of MDS. While a vast majority of patients harbor recurrent mutations implicated in MDS pathogenesis, similar mutations can be detected in otherwise healthy individuals with other hematologic malignancies. Besides establishing a diagnosis, NGS may be used to monitor minimal residual disease following treatment. Expert opinion : As more targeted therapies become available, assessment of genetic mutations will become central to individualized therapy selection and may improve diagnostic accuracy and further guide management for each patient. However, multiple challenges remain before NGS can be incorporated into routine clinical practice.